I think generics will always be part of the mix it just won't have the ability to pull the results around all over the place like it has in previous years. I'd say the aim is clearly to have women's health become the biggest segment in the short/medium term. In short, I see Mayne's generic debacle fading into the past and a future emerging of revenue expansion and debt retirement.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.00 |
Change
-0.080(1.57%) |
Mkt cap ! $405.4M | |||
| Open | High | Low | Value | Volume |
| $5.08 | $5.10 | $4.95 | $410.0K | 81.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 634 | $4.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.00 | 125 | 6 |
View Market Depth
| Last trade - 14.21pm 30/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |